| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | MPD; FP17780 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human MVD |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3-4篇关于MVD(Microvessel Density，微血管密度)抗体的参考文献摘要整理：
---
1. **文献名称**：*Tumor angiogenesis correlates with metastasis in invasive breast carcinoma*
**作者**：Weidner N, Semple JP, Welch WR, Folkman J
**摘要**：该研究首次提出通过免疫组化检测肿瘤微血管密度(MVD)作为血管生成的标志物，使用CD34抗体标记血管内皮细胞，发现MVD与乳腺癌转移风险显著相关，为肿瘤预后评估提供了新方法。
2. **文献名称**：*Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation*
**作者**：Vermeulen PB, Gasparini G, Fox SB, et al.
**摘要**：多中心研究提出标准化MVD检测流程，推荐使用CD31或CD105抗体标记新生血管，强调抗体选择、染色区域界定和计数方法对结果一致性的影响，为临床研究提供统一标准。
3. **文献名称**：*Prognostic value of microvessel density in colorectal cancer: a meta-analysis*
**作者**：Uzzan B, Nicolas P, Cucherat M, Perret GY
**摘要**：Meta分析汇总了40项研究数据，指出通过CD31或CD34抗体检测的高MVD与结直肠癌患者总生存率降低相关，支持MVD作为独立预后因子，但强调抗体选择和检测方法需进一步标准化。
4. **文献名称**：*CD105 (endoglin) as a marker of tumor vasculature in breast cancer*
**作者**：Dales JP, Garcia S, Bonnier P, et al.
**摘要**：研究比较CD105与CD31抗体在乳腺癌中的特异性，发现CD105更倾向标记新生血管，其MVD值与肿瘤进展关联更显著，提示抗体选择影响血管生成评估的准确性。
---
**注**：MVD通常通过免疫组化染色血管内皮标志物(如CD31、CD34、CD105)实现，上述文献涵盖了方法学建立、标准化争议及临床预后意义，均为该领域经典或高引研究。如需具体全文，建议通过PubMed或Web of Science按标题查询。
MVD (mevalonate diphosphate decarboxylase) is a key enzyme in the mevalonate pathway, a metabolic route critical for cholesterol biosynthesis and the production of isoprenoids. It catalyzes the decarboxylation of mevalonate-5-diphosphate to isopentenyl pyrophosphate (IPP), a precursor for sterols and non-sterol metabolites. Dysregulation of this pathway is linked to metabolic disorders, cardiovascular diseases, and cancers. Antibodies targeting MVD have emerged as essential tools for studying its expression, localization, and function in both physiological and pathological contexts.
Research using MVD antibodies has revealed its overexpression in certain cancers, suggesting its potential as a therapeutic target. In inherited metabolic diseases like mevalonic aciduria, MVD mutations disrupt enzyme activity, leading to toxic intermediate accumulation. Antibodies enable detection of these mutations in clinical diagnostics. Additionally, MVD inhibitors are explored for cholesterol-lowering therapies, with antibodies aiding in drug development by monitoring enzyme inhibition.
Despite their utility, challenges remain in ensuring antibody specificity due to structural similarities with other decarboxylases. Advances in recombinant protein technology and epitope mapping continue to refine MVD antibody reliability. Overall, these antibodies bridge basic research and translational applications, offering insights into metabolic regulation and disease mechanisms.
×
